Expression of the psoriasis-associated antigen, pso p27, is inhibited by cyclosporin A

Acta Dermato-Venereologica

Volumn 79, Issue 4, 1999, Pages 281-284

  Dalaker, Morten ^a   Jacobsen, Trond ^a   Lysvand, Hilde ^a   Iversen, Ole Jan ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cyclosporin A; Pathogenesis; pso p27; Psoriasis

Indexed keywords

CYCLOSPORIN A; MONOCLONAL ANTIBODY; PROTEIN P27; TRYPTASE;

ADOLESCENT; ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; ARTICLE; CASE REPORT; CHILD; COMPLEMENT ACTIVATION; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; MALE; PRIORITY JOURNAL; PSORIASIS; SKIN BIOPSY; SKIN INFLAMMATION;

ADULT; ANTIGENS; BIOPSY; CYCLOSPORINE; DERMATOLOGIC AGENTS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 0032968338     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/000155599750010661     Document Type: Article

References (13)

1. 1. Iversen O-J, Rødahl E. The major internal protein, p27, of a retrovirus-like particle participates in immune complex formation in psoriasis. Arch Virol 1985; 86: 37-45.
2. 2. Aasbakk K, Bergh K, Iversen O-J. The psoriasis-associated antigen, pso p27, participates in the formation or complement activating immune complexes in psoriatic scale. APMIS 1990; 98: 143-149.
3. 3. Iversen O-J, Bergh K, Lysvand H. Use of scale antibodies for the detection of antigens in psoriatic lesions. Acta Derm Venereol 1993; 73: 31-34.
4. 4. Iversen O-J, Lysvand H, Jacobsen T, Bergh K, Lie BA. The psoriasis-associated antigen, pso p27, is expressed by tryptase positive cells in psoriatic lesions. Arch Dermatol Res 1995; 287: 503-505.
5. 5. Iversen O-J, Lysvand H, Bergh K, Eriksen J, Elsayed S. The N-terminal amino acid sequence of the psoriasis-associated antigen, pso p27. Arch Dermatol Res 1995; 287: 761-763.
6. 6. Witkamp L, Meinardi MMHM, Bossuyt PMM, Van de Kerkhof PCM, Arnold WP, De Hoop D, et al. A multicentre evaluation of the guidelines for the use of cyclosporin A in severe psoriasis. J Eur Acad Dermatol Venereol 1996; 7: 49-58.
7. 7. Frediksson T, Pettersson U. Severe psoriasis oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
8. 8. Bergh K, Iversen O-J, Aasbakk K. Monoclonal antibodies against the major zymosan-induced chemotactic factor in rabbit serum. J Immunol Methods 1988; 108: 179-187.
9. 9. Jacobsen T, Lie BA, Lysvand H. Wiig M, Pettersen HB, Iversen OJ. Detection of psoriasis-associated antigen pso p27 in sarcoidosis bronchoalveolar lavage fluid using monoclonal antibodies. Clin Immunol Immunopathol 1996; 81: 82-87.
10. 10. Farber EM, Nickoloff BJ, Recht B, Fräki JE. Stress, symmetry and psoriasis: possible role of neuropeptides. J Am Acad Dermatol 1986; 14: 305-311.
11. 11. Iversen O-J, Bergh K, Lysvand H, Jørstad S, Johnsson M, Kvernes S. Cascade apheresis in patients with psoriasis and psoriasis arthritis: effects on the expression of the psoriasis associated antigen pso p27 in skin lesions. Blood Purif 1993; 11: 204-205.
12. 12. Schupack J, Abel E, Bauer E, Brown M, Drake L, Freinekel R, et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol 1997; 36: 423-432.
13. 13. Wong RL, Winslow ChM, Cooper KD. The mechanisms of action of cyclosporin A in the treatment of psoriasis. Immunol Today 1993; Vol 14: 69-74.